We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Precision
Our proprietary chRDNA (CRISPR hybrid RNA-DNA) technology enables improved genome-editing specificity at high efficiency, and we are applying chRDNA to develop sophisticated genome-edited cell therapies.
Allogeneic
Building upon the early successes of autologous cell therapies, we are developing next-generation allogeneic CAR-T and CAR-NK cell therapies with significant potential to address the limitations of patient-derived treatments.
Persistence
We believe persistence is the key to developing successful allogeneic cell therapies. We use our proprietary technologies to enhance persistence by preventing rejection or rapid exhaustion of donor-derived cell therapies.
“Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technology to develop allogeneic cell therapies that are potentially transformative for patients.”
Jennifer Doudna, Ph.D.
Co-founder of Caribou
Co-recipient of the 2020 Nobel Prize in Chemistry
Join the Herd
Caribou Biosciences is a pioneer at the cutting edge of genome editing and cell therapy development, and we are seeking talented and passionate individuals to join our team.
